Atrium Therapeutics, Inc. (RNA)
Every figure this model derived for RNA, the value it took, and the element in the company's own XBRL it was read from — so any of it can be checked against the filing rather than taken on trust. As at 2026-06-30.
The figures, and where each came from
This is the part no other screener shows. Each figure below names the XBRL element it was read from, so it can be checked against the filing itself.
| Figure | Value | XBRL tag | As at |
|---|---|---|---|
| capex | 2,134,000 | PaymentsToAcquirePropertyPlantAndEquipment |
2026-06-30 |
| cash | 263,900,000 | CashAndCashEquivalentsAtCarryingValue |
2026-06-30 |
| current assets | 275,051,000 | AssetsCurrent |
2026-06-30 |
| current liabilities | 31,508,000 | LiabilitiesCurrent |
2026-06-30 |
| equity | 214,576,000 | StockholdersEquity |
2026-06-30 |
| ocf | -35,069,000 | NetCashProvidedByUsedInOperatingActivities |
2026-06-30 |
| revenue | 22,639,000 | RevenueFromContractWithCustomerExcludingAssessedTax |
2026-06-30 |
| sbc | 13,106,000 | ShareBasedCompensation |
2026-06-30 |
The ratios
The figures themselves rather than their scores — what somebody looking up RNA on one particular measure came for.
| Ratio | Value |
|---|---|
| cash operating margin | -116.16 |
| current ratio | 12.24 |
| current ratio reported | 8.73 |
| fcf margin | -164.33 |
| operating margin | -176.24 |
| owner earnings margin | -222.22 |
| revenue growth | 317.69 |
| revenue growth per share | 317.69 |
| rule of 40 | 141.46 |
| sbc pct revenue | 57.89 |
Everything else this filing tags
87 more elements from RNA's own XBRL that this model has no measure for, newest reading each, largest first. Nothing here is converted, added up or renamed — it is the filing's own element names and the filing's own numbers.
| Element | Newest | As of | Periods | Unit |
|---|---|---|---|---|
CommonStockSharesAuthorized | 400,000,000 | 2026-06-30 | 4 | shares |
NetCashProvidedByUsedInFinancingActivities | 301,505,000 | 2026-06-30 | 4 | USD |
ProceedsFromContributionsFromAffiliates | 301,505,000 | 2026-06-30 | 4 | USD |
Assets | 280,512,000 | 2026-06-30 | 4 | USD |
LiabilitiesAndStockholdersEquity | 280,512,000 | 2026-06-30 | 4 | USD |
Cash | 270,000,000 | 2026-02-26 | 2 | USD |
AssetsFairValueDisclosure | 260,901,000 | 2026-06-30 | 2 | USD |
AdditionalPaidInCapital | 222,853,000 | 2026-06-30 | 4 | USD |
NetCashProvidedByUsedInInvestingActivities | -193,685,000 | 2026-06-30 | 4 | USD |
DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss | 191,801,000 | 2026-06-30 | 1 | USD |
DebtSecuritiesAvailableForSaleExcludingAccruedInterest | 191,566,000 | 2026-06-30 | 1 | USD |
ShortTermInvestments | 191,566,000 | 2026-06-30 | 2 | USD |
PaymentsToAcquireAvailableForSaleSecuritiesDebt | 191,551,000 | 2026-06-30 | 1 | USD |
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months | 186,577,000 | 2026-06-30 | 1 | USD |
DebtSecuritiesAvailableForSaleUnrealizedLossPosition | 186,577,000 | 2026-06-30 | 1 | USD |
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents | 72,751,000 | 2026-06-30 | 8 | USD |
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect | 72,751,000 | 2026-06-30 | 4 | USD |
Liabilities | 65,936,000 | 2026-06-30 | 4 | USD |
OperatingExpenses | 62,537,000 | 2026-06-30 | 6 | USD |
ContractWithCustomerLiability | 42,691,000 | 2026-06-30 | 10 | USD |
PreferredStockSharesAuthorized | 40,000,000 | 2026-06-30 | 2 | shares |
OperatingIncomeLoss | -39,898,000 | 2026-06-30 | 6 | USD |
ComprehensiveIncomeNetOfTax | -37,054,000 | 2026-06-30 | 4 | USD |
NetIncomeLoss | -36,819,000 | 2026-06-30 | 8 | USD |
ProfitLoss | -36,819,000 | 2026-06-30 | 4 | USD |
ContractWithCustomerLiabilityNoncurrent | 33,653,000 | 2026-06-30 | 4 | USD |
ResearchAndDevelopmentExpense | 32,000,000 | 2026-06-30 | 6 | USD |
GeneralAndAdministrativeExpense | 30,537,000 | 2026-06-30 | 6 | USD |
CommonStockSharesIssued | 17,106,000 | 2026-06-30 | 4 | shares |
CommonStockSharesOutstanding | 17,106,000 | 2026-06-30 | 4 | shares |
WeightedAverageNumberOfDilutedSharesOutstanding | 17,106,000 | 2026-06-30 | 6 | shares |
WeightedAverageNumberOfSharesOutstandingBasic | 17,106,000 | 2026-06-30 | 6 | shares |
IncreaseDecreaseInAccountsReceivable | 15,000,000 | 2026-03-31 | 2 | USD |
AccruedLiabilitiesCurrent | 13,312,000 | 2026-06-30 | 4 | USD |
AllocatedShareBasedCompensationExpense | 13,106,000 | 2026-06-30 | 6 | USD |
ContractWithCustomerLiabilityCurrent | 9,038,000 | 2026-06-30 | 4 | USD |
RetainedEarningsAccumulatedDeficit | -8,058,000 | 2026-06-30 | 4 | USD |
IncreaseDecreaseInContractWithCustomerLiability | -7,639,000 | 2026-06-30 | 4 | USD |
OtherAssetsCurrent | 6,334,000 | 2026-06-30 | 4 | USD |
OtherAccruedLiabilitiesCurrent | 5,722,000 | 2026-06-30 | 4 | USD |
IncreaseDecreaseInOtherCurrentAssets | 5,024,000 | 2026-06-30 | 4 | USD |
PrepaidExpenseCurrent | 4,506,000 | 2026-06-30 | 4 | USD |
IncreaseDecreaseInAccruedLiabilities | 4,334,000 | 2026-06-30 | 4 | USD |
PropertyPlantAndEquipmentNet | 4,066,000 | 2026-06-30 | 4 | USD |
AccountsPayableCurrent | 3,513,000 | 2026-06-30 | 4 | USD |
NonoperatingIncomeExpense | 3,079,000 | 2026-06-30 | 6 | USD |
ContractWithCustomerLiabilityRevenueRecognized | 3,004,000 | 2026-06-30 | 6 | USD |
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets | 2,971,000 | 2026-06-30 | 4 | USD |
InterestIncomeOther | 2,757,000 | 2026-06-30 | 4 | USD |
IncreaseDecreaseInOperatingLeaseLiability | -2,026,000 | 2026-06-30 | 4 | USD |
OperatingLeaseLiabilityCurrent | 1,683,000 | 2026-06-30 | 4 | USD |
OperatingLeaseRightOfUseAssetAmortizationExpense | 1,595,000 | 2026-06-30 | 4 | USD |
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount | 1,393,000 | 2026-06-30 | 3 | shares |
DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss | 1,300,000 | 2026-06-30 | 1 | USD |
OperatingLeaseRightOfUseAsset | 1,289,000 | 2026-06-30 | 4 | USD |
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue | 893,000 | 2026-06-30 | 3 | USD |
IncreaseDecreaseInAccountsPayable | -885,000 | 2026-06-30 | 4 | USD |
IncreaseDecreaseInEmployeeRelatedLiabilities | 815,000 | 2026-06-30 | 4 | USD |
OtherLiabilitiesNoncurrent | 775,000 | 2026-06-30 | 4 | USD |
Depreciation | 494,000 | 2026-06-30 | 4 | USD |
OtherNonoperatingIncomeExpense | 322,000 | 2026-06-30 | 4 | USD |
RestrictedCashCurrent | 311,000 | 2026-06-30 | 3 | USD |
AccretionAmortizationOfDiscountsAndPremiumsInvestments | 250,000 | 2026-06-30 | 2 | USD |
AccumulatedOtherComprehensiveIncomeLossNetOfTax | -235,000 | 2026-06-30 | 2 | USD |
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax | 235,000 | 2026-06-30 | 1 | USD |
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss | 235,000 | 2026-06-30 | 1 | USD |
DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss | 235,000 | 2026-06-30 | 1 | USD |
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax | -235,000 | 2026-06-30 | 4 | USD |
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax | -235,000 | 2026-06-30 | 1 | USD |
IncreaseDecreaseInOtherNoncurrentLiabilities | 201,000 | 2026-06-30 | 4 | USD |
RestrictedCashNoncurrent | 106,000 | 2026-06-30 | 6 | USD |
CommonStockValue | 16,000 | 2026-06-30 | 4 | USD |
EarningsPerShareBasic | -2 | 2026-06-30 | 6 | USD/shares |
EarningsPerShareDiluted | -2 | 2026-06-30 | 6 | USD/shares |
NetAssetValuePerShare | 1 | 2026-06-30 | 2 | USD/shares |
NumberOfOperatingSegments | 1 | 2026-06-30 | 2 | Segment |
NumberOfReportableSegments | 1 | 2026-06-30 | 2 | Segment |
CommonStockParOrStatedValuePerShare | 0 | 2026-06-30 | 4 | USD/shares |
PreferredStockParOrStatedValuePerShare | 0 | 2026-06-30 | 2 | USD/shares |
FairValueOfAssetsAcquired | 0 | 2026-06-30 | 4 | USD |
PreferredStockSharesIssued | 0 | 2026-06-30 | 4 | shares |
PreferredStockSharesOutstanding | 0 | 2026-06-30 | 4 | shares |
ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod | 0 | 2026-03-31 | 1 | shares |
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax | 0 | 2026-06-30 | 1 | USD |
CapitalExpendituresIncurredButNotYetPaid | 0 | 2026-06-30 | 2 | USD |
DebtSecuritiesAvailableForSaleAccruedInterestWriteoff | 0 | 2026-06-30 | 1 | USD |
DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest | 0 | 2026-06-30 | 1 | USD |
What to be careful about
What this model itself distrusts about RNA's figures. Written by the derivation as it ran, not added afterwards.
- only 180 days of filings, not a full year: margins and growth are measured, but return on capital and every enterprise-value multiple are refused rather than annualised
- no usable diluted share count, so growth is measured on total revenue rather than per share; a company issuing shares to fund that growth reads better than it is
- no debt and no profit, so interest cover cannot be measured; scored on cash runway instead: 264M of net cash against a 37M annual burn is 7.1 years
- analyst estimate not used: trailing EPS is not positive, so a growth rate would be meaningless
- quality rests on 4 of 5 inputs; not tagged: roic
- valuation DROPPED from the total: only 0 of 2 inputs could be computed (ev ebit, ev owner earnings not tagged), so the score is not meaningful. Its weight is spread over the other dimensions
- durability DROPPED from the total: only 0 of 4 inputs could be computed (worst year, contracted coverage, gross margin stability, cash flow stability not tagged), so the score is not meaningful. Its weight is spread over the other dimensions
- growth DROPPED from the total: only 1 of 4 inputs could be computed (sustained growth, margin trend, margin recent not tagged), so the score is not meaningful. Its weight is spread over the other dimensions
- 3 of 5 dimensions could not be measured (valuation, durability, growth -- 55% of the model), so this row is not comparable with the others; its total rests on what was left